Monarch Weather Consulting Launches Weather Intelligence GIS Content Solutions on Esri’s ArcGIS Marketplace
SAN DIEGO–(BUSINESS WIRE)–As the entrepreneurs behind Monarch Weather Consulting, meteorologists Crystal Egger and Kathryn Prociv…
Month: February 2022
Ingram Micro Expands Hyper Automation Practice; Welcomes Industry Leader Alkymi Inc.
New Alliance Expands Alkymi’s Reach into Channel and Introduces Intelligent Document Processing (IDP) and Additional…
Driver Management Nominates Three Highly-Qualified, Independent Candidates for Election to Codorus Valley Bancorp’s Board of Directors
Calls for Meaningful, Shareholder-Driven Change in Codorus Valley’s Boardroom Decries Status Quo That Serves Management…
Turning Point Therapeutics to Participate in Upcoming Investor Conferences
SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a…
XBiotech Inks Clinical Manufacturing Deal
XBiotech Manufacturing Antibody Drug for Janssen Research & Development, LLC (Janssen), One of the Janssen…
Yield10 Bioscience Receives Favorable Ruling from the Argentine Biosafety Commission (CONABIA) for Company’s Camelina Lines
Three Yield10 CRISPR Genome-Edited Camelina Lines Were Determined to be Similar to Conventional Camelina Varieties…
Teclison Announces the Appointment of Wan Lung Eng as Chief Financial Officer
PRINCETON, N.J., Feb. 02, 2022 (GLOBE NEWSWIRE) — Teclison, a clinical-stage pharmaceutical company developing novel…
CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D)
ZUG, Switzerland, and CAMBRIDGE, Mass., and SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) — CRISPR…
Quotient Limited Announces Equity Awards
JERSEY, Channel Islands, Feb. 02, 2022 (GLOBE NEWSWIRE) — Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics…
Outlook Therapeutics to Present at the Fourth Annual Telluride Retina Film Festival
ISELIN, N.J., Feb. 02, 2022 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical…
TRACON Pharmaceuticals Announces Initiation of Randomized Phase 2 Trial of TRC102 in Lung Cancer Sponsored by the National Cancer Institute
SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage…
ABVC BioPharma Announces Principal Investigator Meeting for Phase II Part 2 ADHD Clinical Study
Fremont, CA, Feb. 02, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — ABVC Biopharma, Inc. (NASDAQ:…
Reneo Pharmaceuticals to Participate in SVB Leerink Virtual Global Healthcare Conference
IRVINE, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical…
VBL Therapeutics to Participate in the Guggenheim Oncology Conference and the 2022 BIO CEO & Investor Conference
TEL AVIV, Israel and NEW YORK, Feb. 02, 2022 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq:…
Achieve Life Sciences Announces Participation in February Investor Conferences
SEATTLE and VANCOUVER, British Columbia, Feb. 02, 2022 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc….
Bluejay Therapeutics Announces the Appointment of Nancy Shulman, M.D., as Chief Medical Officer
SAN MATEO, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) — Bluejay Therapeutics, a private biopharmaceutical company…
Fate Therapeutics to Present at Upcoming February Investor Conferences
SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (the “Company” or “Fate…
Bolt Biotherapeutics to Participate in Upcoming February Conferences
REDWOOD CITY, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) — Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage…
PDS Biotech Announces Preliminary Efficacy Achievement in VERSATILE-002 Phase 2 Trial of PDS0101 in Combination With KEYTRUDA® (pembrolizumab) in Advanced Head and Neck Cancer
Achievement of initial efficacy milestone allows full enrollment of checkpoint inhibitor naïve cohort FLORHAM PARK,…
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 02, 2022 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled…